Combining pharmacotherapy and psychotherapy - General principles;Kombinationsbehandlung von psychotherapie und pharmakotherapie- Allgemeine grundlagen

Zeitschrift fur Psychiatrie, Psychologie und Psychotherapie

Volumn 54, Issue 3, 2006, Pages 155-161

  Klein, Jan Philipp ^a   Schweiger, Ulrich ^a   Hohagen, Fritz ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Combined treatment; Pharmacotherapy; Psychotherapy; Review

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; DOXEPIN; DULOXETINE; FLUOXETINE; FLUPENTIXOL; HALOPERIDOL; IMIPRAMINE; LAMOTRIGINE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PERAZINE; REBOXETINE; RISPERIDONE; SERTRALINE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; ZUCLOPENTHIXOL;

ALLERGIC REACTION; ANXIETY DISORDER; ATAXIA; CONSTIPATION; DEPRESSION; DRUG EFFECT; EXTRAPYRAMIDAL SYNDROME; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; LEARNING DISORDER; MANIA; MOTOR DYSFUNCTION; NAUSEA; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; ORTHOSTATIC HYPOTENSION; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; RELAPSE; REMISSION; REVIEW; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SWEATING; THYROID DISEASE; TREMOR; XEROSTOMIA;

EID: 33746506135     PISSN: 16614747     EISSN: None     Source Type: Journal    
DOI: 10.1024/1661-4747.54.3.155     Document Type: Review

References (48)

1. Barlow, D. H., Gorman, J. M., Shear, M. K. & Woods, S. W. (2000). Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. Journal of the American Medical Association, 283, 2529-2536.
2. Basoglu, M., Marks, I. M., Kilic, C., Brewin, C. R. & Swinson, R. P. (1994). Alprazolam and exposure for panic disorder with agoraphobia. Attribution of improvement to medication predicts subsequent relapse. British Journal of Psychiatry, 164, 652-659.
3. Bauer, M. S. & Mitchner, L. (2004). What is a «mood stabilizer»? An evidence-based response. American Journal of Psychiatry, 161, 3-18.
4. Belmaker, R. H. (2004). Bipolar disorder. New England Journal of Medicine, 351, 476-486.
5. Bouton, M. E., Kenney, F. A. & Rosengard, C. (1990). State-dependent fear extinction with benzodiazepine tranquilizers. Behavioral Neuroscience, 104, 44-55.
6. Bouvard, M., Mollard, E., Guerin, J. & Cottraux, J. (1997). Study course of the psychological profile in 77 patients expressing panic disorder with agoraphobia after cognitive therapy with or without buspirone. Psychotherapy and Psychosomatics, 66, 27-32.
7. Browne, G., Steiner, M., Roberts, J., Gafni, A., Byrne, C., Dunn, E., Bel, B., Mills, M., Chalkin, L., Wallik, D. & Kraemer, J. (2002). Sertraline and/or interpersonal psychotherapy for patients with dysthymic disorder in primary care: 6-month comparison with longitudinal 2-year-follow-up of effectiveness and costs. Journal of Affective Disorder, 68, 317-330.
8. Buysse, D. J., Reynolds, C. F. 3rd, Houck, P. R., Perel, J. M., Frank, E., Begley, A. E., Mazumdar, S. & Kupfer, D. J. (1997). Does lorazepam impair the antidepressant response to nortriptyline and psychotherapy? Journal of Clinical Psychiatry, 58, 426-432.
9. Cipriani, A., Pretty, H., Hawton, K. & Geddes, J. R. (2005). Lithium in the prevention of suicidal behaviour and all-cause mortality in patients with mood-disorders: a systematic review of randomized trials. American Journal of Psychiatry, 162, 1805-1819.
10. Cottraux, J., Mollard, E., Bouvard, M., Marks, I., Sluys, M., Nury, A. M., Douge, R. & Cialdella, P. (1990). A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder. International Clinical Psychopharmacology, 5, 17-30.
11. Cottraux, J., Note, I. D., Cungi, C., Legeron, P., Heim, F., Chneiweiss, E., Bernard, G. & Bouvard, M. (1995). A controlled study of cognitive behaviour therapy with buspirone or placebo in panic disorder with agoraphobia. British Journal of Psychiatry, 167, 635-641.
12. de Beurs, E., van Balkom, A. J., Van Dyck, R. & Lange, A. (1999). Long-term outcome of pharmacological and psychological treatment for panic disorder with agoraphobia: A 2-year naturalistic follow-up. Acta Psychiatrica Scandinavica, 99, 59-67.
13. de Jong-Meyer, R., Hautzinger, M. & Rudolf, G. A. E. (1996). The effectiveness of antidepressants an cognitive behavioural therapy, combined in patients with endogenous depression: Results of analyses of variance regarding main and secondary outcome criteria. Zeitschrift für klinische Psychologie, 25, 93-109.
14. Drury, V., Birchwood, M., Cochrane, R. & Macmillan, F. (1996). Cognitive therapy and recovery from acute psychosis: A controlled trial. II. Impact on recovery time. British Journal of Psychiatry, 169, 602-607.
15. Frank, E., Grochocinski, V. J., Spanier, C. A., Buysse, D. J., Cherry, C. R., Houck, P. R., Stapf, D. M. & Kupfer, D. J. (2000). Interpersonal psychotherapy and antidepressant medication: Evaluation of a sequential treatment strategy in women with recurrent major depression. Journal of Clinical Psychiatry, 61, 51-57.
16. Frank, E., Kupfer, D. J., Perel, J. M., Cornes, C., Jarrett, D. B., Mallinger, A.G., Thase, M.E., McEachran, A.B. & Grochocinski, V. J. (1990). Three-year outcomes for maintenance therapies in recurrent depression. Archives of General Psychiatry, 47, 1093-1009.
17. Franklin, M. E., Foa, E. B., Liebowitz, M. R., Kozak, M. J., Campeas, R. & Davies, S. (2002). A controlled study of exposure therapy, clomipramine, and combination for OCD. Poster session presented at the annual meeting of the American Psychiatric Association.
18. Zitiert nach Foa, E. B., Franklin, M. E. & Moser, J. (2002). Context in the clinic: How well do cognitive-behavioral therapies and medications work in combination? Biological Psychiatry, 52, 987-997.
19. Freedman, R. (2003). Schizophrenia. New England Journal of Medicine, 349, 1738-1749.
20. Hoffart, A., Due-Madsen, J., Lande, B., Gude, T., Bille, H. & Torgersen, S. (1993). Clomipramine in the treatment of agoraphobic inpatients resistant to behavioral therapy. Journal of Clinical Psychiatry, 54, 481-487.
21. Hohagen, F., Winkelmann, G., Rasche-Ruchle, H., Hand, I., Konig, A., Munchau, N., Hiss, H., Geiger-Kabisch, C., Kappler, C., Schramm, P., Rey, E., Aldenhoff, J. & Berger, M. (1998). Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo. Results of a multicentre study. British Journal of Psychiatry, 173 (Suppl.35), 71-78.
22. Holsboer, F. (2000). The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology, 23, 477-501.
23. Kampmann, M., Keijsers, G. P., Hoogduin, C. A. & Hendriks, G. J. (2002). A randomized, double-blind, placebo-controlled study of the effects of adjunctive paroxetine in panic disorder patients unsuccessfully treated with cognitive-behavioral therapy alone. Journal of Clinical Psychiatry, 63, 772-777.
24. Keller, M. B., McCullough, J. P., Klein, D. N., Arnow, B., Dunner, D. L., Gelenberg, A. J., Markowitz, J. C., Nemeroff, C. B., Russell, J. M., Thase, M. E., Trivedi, M. H. & Zajecka, J. (2000). A comparison of nefazodone, the cognitive behavioral-analy-sis system of psychotherapy, and their combination for the treatment of chronic depression. New England Journal of Medicine, 342, 1462-1470.
25. Kuipers, E., Garety, P., Fowler, D., Dunn, G., Bebbington, P., Freeman, D. & Hadley, C. (1997). London-East Anglia randomised controlled trial of cognitive-behavioural therapy for psychosis. I: effects of the treatment phase. British Journal of Psychiatry, 171, 319-327.
26. Lenze, E. J., Dew, M. A., Mazumdar, S., Begley, A. E., Cornes, C., Miller, M. D., Imber, S. D., Frank, E., Kupfer, D. J. & Reynolds, C. F. 3rd (2002). Combined pharmacotherapy and psychotherapy as maintenance treatment for late-life depression: Effects on social adjustment. American Journal of Psychiatry, 159, 466-468.
27. Low, K., Crestani, F., Keist, R., Benke, D., Brunig, I., Benson, J. A., Fritschy, J. M., Rulicke, T., Bluethmann, H., Mohler, H. & Rudolph, U. (2000). Molecular and neuronal substrate for the selective attenuation of anxiety. Science, 290, 131-134.
28. Mann, J. J. (2005). The medical management of depression. New England Journal of Medicine, 353, 1819-1834.
29. Marks, I. M., Swinson, R. P., Basoglu, M., Kuch, K., Noshirvani, H., O'Sullivan, G., Lelliott, P. T., Kirby, M., McNamee, G., Sengun, S. & Wickwire, K. (1993). Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto. British Journal of Psychiatry, 162, 776-787.
30. Mavissakalian, M., Perel, J. & Guo, S. (2002). Specific side effects of long-term imipramine management of panic disorder. Journal of Clinical Psychopharmacology, 22, 155-161.
31. Muller-Oerlinghausen, B., Berghofer, A. & Bauer, M. (2002). Bipolar disorder. Lancet, 359, 241-247.
32. Nemeroff, C. B., Heim, C. M., Thase, M.E., Klein, D.N., Rush, A. J., Schatzberg, A. F., Ninan, P. T., McCullough, J. P. Jr., Weiss, P. M., Dunner, D. L., Rothbaum, B. O., Kornstein, S., Keitner, G. & Keller, M.B. (2003). Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proceedings of the National Academy of Sciences, 100, 14293-14296.
33. Oehrberg, S., Christiansen, P. E., Behnke, K., Borup, A. L., Severin, B., Soegaard, J., Calberg, H., Judge, R., Ohrstrom, J. K. & Manniche, P. M. (1995). Paroxetine in the treatment of panic disorder: A randomised, double-blind, placebo-controlled study. British Journal of Psychiatry, 167, 374-379.
34. Pariante, C. M. & Miller, A. H. (2001). Glucocorticoid receptor hypothesis of depression: Relevance to pathophysiology and treatment. Biological Psychiatry, 49, 391-404.
35. Park, H., Quinlan, J., Thornton, E. & Reder, L. M. (2004). The effect of midazolam on visual search: Implications for understanding amnesia. Proceedings of the National Academy of Sciences, 101, 17879-17883.
36. Paykel, E. S., Scott, J., Teasdale, J. D., Johnson, A. L., Garland, A., Moore, R., Jenaway, A., Cornwall, P. L., Hayhurst, H., Abbott, R. & Pope, M. (1999). Prevention of relapse in residual depression by cognitive therapy: A controlled trial. Archives of General Psychiatry, 56, 829-835.
37. Pelissolo, A. & Lepine, J. P. (1999). Pharmacotherapy in personality disorders: Methodological issues and results. Encephale, 25, 496-507.
38. Perus, R. H., Nierenberg, A. A., Alpert, J. E., Pava, J., Matthews, J. D., Buchin, J., Sickinger, A. H. & Fava, M. (2002). Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder. Journal of Clinical Psychopharmacology, 22, 474-480.
39. Reynolds, C. F. 3rd, Frank, E., Perel, J.M., Imber, S.D., Cornes, C., Miller, M. D., Mazumdar, S., Houck, P. R., Dew, M. A., Stack, J. A., Pollock, B. G. & Kupfer, D. J. (1999). Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: A randomized controlled trial in patients older than 59 years. Journal of the American Medial Association, 281, 39-45.
40. Reynolds, C. F. 3rd, Dew, M. A., Pollock, B. G., Mulsant, B. H., Frank, E., Miller, M. D., Houck, P. R., Mazumdar, S., Butters, M. A., Stack, J. A., Schlernitzauer, M. A., Whyte, E. M., Gildengers, A., Karp, J., Lenze, E., Szanto, K., Bensasi, S. & Kupfer, D. J. (2006). Maintenance therapy of major depression in old age. New England Journal of Medicine, 354, 1130-1138.
41. Rudolph, U., Crestani, F., Benke, D., Brunig, I., Benson, J. A., Fritschy, J. M., Martin, J. R., Bluethmann, H. & Mohler, H. (1999). Benzodiazepine actions mediated by specific γ-aminobutyric acid(A) receptor subtypes. Nature, 401, 796-800.
42. Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., Belzung, C. & Hen, R. (2003). Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science, 301, 805-809.
43. Sapolsky, R. M. (2000). Glucocorticoids and hippocampal atrophy in neuropsychiatrie disorders. Archives of General Psychiatry, 57, 925-935.
44. Schwartz, J. M. (1998). Neuroanatomical aspects of cognitive-behavioural therapy response in obsessive-compulsive disorder. An evolving perspective on brain and behaviour. British Journal of Psychiatry, 173 (Suppl. 35), 38-44.
45. Thase, M. E., Greenhouse, J. B., Frank, E., Reynolds, C. F. 3rd, Pilkonis, P. A., Hurley, K., Grochocinski, V. & Kupfer, D. J. (1997). Treatment of major depression with psychotherapy or psychotherapy- pharmacotherapy combinations. Archives of General Psychiatry, 54, 1009-1015.
46. van Balkom, A. J., de Haan, E., van Oppen, P., Spinhoven, P., Hoogduin, K. A. & van Dyck, R. (1998). Cognitive and behavioral therapies alone versus in combination with fluvoxamine in the treatment of obsessive compulsive disorder. Journal of Nervous and Mental Disease, 186, 492-499.
47. Vythilingam, M., Vermetten, E., Anderson, G. M., Luckenbaugh, D., Anderson, E. R., Snow, J., Staib, L. H., Charney, D. S. & Bremner, J. D. (2004). Hippocampal volume, memory, and cortisol status in major depressive disorder: effects of treatment. Biological Psychiatry, 56, 101-112.
48. Wilhelm, F. H. & Roth, W. T. (1997). Acute and delayed effects of alprazolam on flight phobies during exposure. Behaviour research and therapy, 35, 831-841.